Conditions: Pulmonary Disease, Chronic Obstructive
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 2080
Healthy volunteers: no

Brief summary:
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives include comparing the effects on dyspnea and health status.

Detailed description:

Arms:
arm 1: Matching Placebo arm 2: Low dose arm 3: Medium dose arm 4: High dose arm 5: Tiotropium Bromide

Interventions: intervention 1: BEA 2180 BR intervention 2: Tiotropium Bromide intervention 3: Placebo
Intervention descriptions: intervention 1: Solution intervention 2: Solution intervention 3: Solution

Protocol document: